134 related articles for article (PubMed ID: 12681989)
1. Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Wölfler A; Bauer F; Zollner G; Weber K; Sill H; Linkesch W
Haematologica; 2003 Apr; 88(4):ELT12. PubMed ID: 12681989
[No Abstract] [Full Text] [Related]
2. Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma.
Huston A; Brown J; Roodman GD
Exp Hematol; 2006 Dec; 34(12):1616. PubMed ID: 17157156
[No Abstract] [Full Text] [Related]
3. Toxic epidermal necrolysis following thalidomide and dexamethasone treatment for multiple myeloma: a case report.
Eo WK; Kim SH; Cheon SH; Lee SH; Jeong JS; Kim YS; Chang HK; Suh KS; Kim HY
Ann Hematol; 2010 Apr; 89(4):421-2. PubMed ID: 19693501
[No Abstract] [Full Text] [Related]
4. Kappa light chain myeloma with initial cutaneous involvement.
Saka B; Erten N; Oztürk G; Yilmaz C; Dogan O; Buyukbabani N; Besisik SK
Ann Hematol; 2006 Apr; 85(4):272-4. PubMed ID: 16425024
[No Abstract] [Full Text] [Related]
5. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
Hassoun H; Reich L; Klimek VM; Dhodapkar M; Cohen A; Kewalramani T; Zimman R; Drake L; Riedel ER; Hedvat CV; Teruya-Feldstein J; Filippa DA; Fleisher M; Nimer SD; Comenzo RL
Br J Haematol; 2006 Jan; 132(2):155-61. PubMed ID: 16398649
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study.
de la Rubia J; Roig M; Ibáñez A; García I; Vera JA; Aguilar C; del Campo R; González N; Martínez R; Palomera L; Picón I; Rodríguez JN; Sanz MA
Eur J Haematol; 2010 Oct; 85(4):363-5. PubMed ID: 20662900
[No Abstract] [Full Text] [Related]
10. Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Bemardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):129-33. PubMed ID: 16767919
[TBL] [Abstract][Full Text] [Related]
11. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
[TBL] [Abstract][Full Text] [Related]
12. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
Ciolli S; Leoni F; Casini C; Breschi C; Santini V; Bosi A
Br J Haematol; 2008 Jun; 141(6):814-9. PubMed ID: 18410447
[TBL] [Abstract][Full Text] [Related]
13. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
17. Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
Sullivan E; Hoyle C
Br J Haematol; 2011 Oct; 155(2):136. PubMed ID: 21605111
[No Abstract] [Full Text] [Related]
18. Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
Boga C; Ozdogu H; Yeral M; Kizilkilic E; Tamer L
J Support Oncol; 2007 Jun; 5(6):256. PubMed ID: 17624049
[No Abstract] [Full Text] [Related]
19. Thalidomide and dexamethasone: therapy for multiple myeloma.
Kumar S; Rajkumar SV
Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
[TBL] [Abstract][Full Text] [Related]
20. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
